New York State Common Retirement Fund Purchases 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

New York State Common Retirement Fund lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 14.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 204,482 shares of the biotechnology company’s stock after buying an additional 25,164 shares during the quarter. New York State Common Retirement Fund’s holdings in Ascendis Pharma A/S were worth $28,151,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Legato Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 7.5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 134 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $30,000. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in Ascendis Pharma A/S by 0.3% in the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after purchasing an additional 228 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ASND. Stifel Nicolaus raised their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $197.36.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $154.58 on Friday. The company’s fifty day simple moving average is $134.09 and its 200-day simple moving average is $132.88. The stock has a market capitalization of $9.38 billion, a PE ratio of -21.77 and a beta of 0.64. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.36 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.